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Open access under CC BChitin is an essential structural component of the fungal cell wall. Chitinases are thought to be impor-
tant for fungal cell wall remodelling, and inhibition of these enzymes has been proposed as a potential
strategy for development of novel anti-fungals. The fungal pathogen Aspergillus fumigatus possesses two
distinct multi-gene chitinase families. Here we explore acetazolamide as a chemical scaffold for the
inhibition of an A. fumigatus ‘plant-type’ chitinase. A co-crystal structure of AfChiA1 with acetazolamide
was used to guide synthesis and screening of acetazolamide analogues that yielded SAR in agreement
with these structural data. Although acetazolamide and its analogues are weak inhibitors of the
enzyme, they have a high ligand efﬁciency and as such are interesting leads for future inhibitor
development.
 2010 Elsevier Ltd. Open access under CC BY license.1. Introduction
Aspergillus fumigatus is the causative agent of aspergillosis, a
life-threatening fungal infection that targets a rising population
of immunocompromised patients.1 Currently available anti-fungal
drugs, such as the azoles, amphotericin B and the candins are only
partially effective2,3 and resistant Aspergillus strains have started to
appear in hospital settings.4,5 Thus there is a need for the identiﬁ-
cation of novel targets and the development of new anti-fungal
agents. Enzymes involved in the biogenesis/turnover of the fungal
cell wall are thought to represent possible targets.
Chitin, a polymer of b(1,4)-linked N-acetylglucosamine
(GlcNAc), is an essential structural component of the fungal cell
wall, giving it structural rigidity and chemical/biological stability.
Because of the inherent rigidity of chitin, fungi need to partially
hydrolyse the chitin layer for cell division and morphogenesis,
which is carried out by family 18 chitinases.6 Two subclasses of
family 18 chitinases exist: the ‘bacterial-type’ chitinases are found
in bacteria, fungi and mammals; the ‘plant-type’ chitinases are
found exclusively in plants and fungi. Whereas the ‘bacterial-type’
enzymes are invariably secreted and mostly possess exochitinase
activity,7–10 the ‘plant-type’ chitinases are frequently cell wall
associated and possess endochitinase activity. Several studies have
shown that these enzymes are involved in yeast mother–daughterx: +44 1382 386 373 (I.H.G.).
(D.M.F. van Aalten), i.h.gil-
Y license.cell separation.11,12 Because these enzymes are not intracellular, it
is possible to explore a wider area of chemical space for inhibitors,
as these would not be required to cross membranes. Whilst
humans possess two active chitinases,13,14 they are of the ‘bacte-
rial-type’, and to date the only inhibitors reported are the large,
hydrophilic natural products, allosamidin,15 argiﬁn,16 argadin17
and the rationally designed drug-like inhibitor C2-dicaffeine.18
There are ﬁve ‘plant-type’ chitinases genes in the A. fumigatus gen-
ome (AfChiA1–5), with a currently unknown transcription proﬁle.
Sequence alignments show that they have a high degree of struc-
tural similarity in the active site, suggesting that it should be pos-
sible to design compounds that inhibit all ﬁve enzymes.
Recently we have cloned and over-expressed the ‘plant-type’
family 18 chitinase Cts1p from Saccharomyces cerevisiae (ScCTS1).19
This enzyme was then screened against the Prestwick chemical
library of 880 drug-like molecules. From this, three signiﬁcant hits
were identiﬁed, 8-chlorotheophylline, acetazolamide and kinetin
(Table 1), all of which were competitive inhibitors of the enzyme
and were shown to bind in the active site groove, interacting with
the catalytic machinery.19
Here we describe a study towards the identiﬁcation of small
inhibitor scaffolds (‘fragments’) against the ‘plant-type’ A. fumiga-
tus enzyme chitinase A1 (AfChiA1). Two novel ScCTS1 inhibitors,
acetazolamide and 8-chlorotheophylline, showed weak inhibition
of AfChiA1. We were able to obtain a crystal structure of AfChiA1
in complex with acetazolamide. A number of derivatives of aceta-
zolamide were prepared or purchased and screened against the
enzyme AfChiA1; a number were identiﬁed with similar activity
to acetazolamide.
Table 1
Inhibitors of ScCTS1 and their activity against AfChiA1
Name Allosamidin 8-Chloro-theophylline Acetazolamide Kinetin
Structure
O
O
O
O
N
O
HO
HO
NHAc
HO
NHAc
HO
OH
OH
OH
NMe2
N
N
N
H
NO
O
Cl
N N
S HNS
O
H2N
O
O
N
N
H
N
N
HN
O
ScCST1 Ki 0.61 340 21 3.2
AfChiA1 IC50 127 410 164 >1000
hCHT IC50 0.04 >2500 >1000 >1000
All data given in lM. hCHT is human chitinase. Data for ScCST1 have been reported previously.19 The IC50 of allosamidin against hCHT has been reported previously.22
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2.1. Acetazolamide is an efﬁcient inhibitor of A. fumigatus
chitinase
Previous work has suggested that the plant-type fungal chitinas-
es may be targets for novel anti-fungal strategies.11,12,20 So far the
only enzyme from this class characterised in some detail is CST1
from S. cerevisiae and the plant enzyme hevamine.6 A. fumigatus chi-
tinase A1 (AfChiA1) also belongs to the class of plant-type chitinases
family, and has been cloned and characterised recently.21
To identify possible inhibitors of AfChiA1, a number of plant-
type chitinase inhibitors previously characterised against ScCTS1
were explored as potential scaffolds (Table 1).19 Allosamidin is an
extensively characterised natural product inhibitor of both plant-
type and bacterial-type family 18 chitinases,15 and has recently
been reported to competitively inhibit ScCTS1 with a Ki of
0.61 lM19 and hevamine with a Ki of 3.1 lM.9 Unfortunately, allos-
amidin is a substrate analogue with poor drug-like properties (high
molecular weight, containing glycosidic bonds and an undesirably
low C log P of 5.2) and the total synthesis is costly and compli-
cated.23 Remarkably, allosamidin only weakly inhibits AfChiA1
(IC50 = 127 lM, Fig. 1),21 which is 30- and 200-fold less potent than
values previously reported against hevamine and ScCTS1, respec-
tively. Examination of the purine derivative 8-chlorotheophylline,
which had previously been demonstrated to inhibit ScCTS1 with
a Ki of 600 lM,19 revealed a similar level of inhibition (IC50 =
410 lM, Fig. 1). Two further compounds, kinetin and acetazola-
mide, have been identiﬁed as ScCTS1 inhibitors by screening the
Prestwick Chemical Library, with Ki values of 3.2 lM and 21 lM,Figure 1. IC50 curves determined in triplicate, ﬁtted to a four-parameter logistic dose–re
for allosamidin (IC50 = 128 lM, Hill slope 0.9), acetazolamide (IC50 = 164 lM, Hill
methylumbelliferyl b-D-N,N0 ,N00-triacetylchitotrioside (4MU-NAG3) as a substrate.respectively.19 Kinetin failed to show any discernable effect against
AfChiA1 even at concentrations in excess of 1 mM; acetazolamide
on the other hand inhibited AfChiA1 with an IC50 of 164 lM
(Fig. 1), which is an order of magnitude less potent than previously
demonstrated against ScCTS1 but not dissimilar to the level of inhi-
bition observed for allosamidin (Fig. 1). It is instructive to compare
the ligand efﬁciencies of the compounds at this stage—that is, the
binding energy per non-hydrogen atom.24 Due to their small size
acetazolamide and 8-chlorotheophylline are the most efﬁcient of
these inhibitors (0.61 and 0.57 kcal mol1 atom1, respec-
tively), compared to allosamidin (0.19 kcal mol1 atom1). Thus,
acetazolamide is a small drug-like molecule that is amenable to
preparation of analogues and represents an attractive starting
point for further elaboration.
2.2. Crystal structure of the AfChiA1–acetazolamide complex
suggests possible derivatives
Of the initial leads investigated, acetazolamide was selected
as the most promising starting point for the development of A.
fumigatus plant-type chitinase inhibitors given its high ligand
efﬁciency. AfChiA1 crystals, reported previously21, were soaked
with acetazolamide, diffraction data were collected to 2.0 Å res-
olution, and the structure of the AfChiA1–acetazolamide complex
was solved by molecular replacement and reﬁned to an Rfree of
0.249 (Table 2) with good stereochemistry. Electron density for
the ligand acetazolamide can be seen in both molecules in the
asymmetric unit, but it is less clear in chain A, where the active
site is partially occluded by a symmetry-related protein mole-
cule. Thus the further discussion of the structure will focus onsponse curve (minimum, Hill slope, inﬂection point and maximum) against AfChiA1
slope 1.1) and 8-chlorotheophylline (IC50 = 410 lM, Hill slope 1.0) using 4-
Table 2
X-ray diffraction/reﬁnement statistics for the AfChiA1–acetazolamide complex
Resolution range (Å) 20.00–2.00 (2.05–2.00)
Number of observed reﬂections 27,0663
Number of unique reﬂections 67,879 (4270)
Completeness (%) 98.1 (92.9)
Redundancy 4.0 (3.5)
I/r(I) 13.5 (2.5)
Rmerge 0.085 (0.522)
Wilson B (Å2) 22.5
Rwork, Rfree 0.216, 0.249
Bond length rmsd from ideality (Å) 0.017
Bond angle rmsd from ideality () 1.5
<B>, overall (Å2) 27.2
<B>, protein (Å2) 26.5
<B>, solvent (Å2) 34.1
<B>, ligand (Å2) 32.1
Ramachandran plot
Most favoured (%) 88.6
Additionally allowed (%) 10.8
Generously allowed (%) 00.2
Values in parentheses pertain to the highest resolution shell. Ramachandran plot
statistics were calculated with PROCHECK.25
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active site.
The overall binding mode of the ligand to AfChiA1 is essentially
identical to that observed for ScCTS1 (Fig. 2B).19 The thiadiazole ring
stacks with the conserved Trp312, while its ring nitrogens accept
hydrogen bonds from the backbone amides of Ala124 and Tyr125,
in the latter case indirectly via an active site-boundwatermolecule.
The acetamido group enters, and essentially ﬁlls, the small AfChiA1
active site pocket formed by Tyr238, Gln230,Met310, Ala205, Tyr34
and Asp172. It is oriented by two hydrogen bonds, one from its
amide to the side chain of Asp172 and one from the Tyr232 side
chain hydroxyl to its carbonyl oxygen. The sulfonamide group on
the other hand forms few direct interactions with the protein: it ac-
cepts a poor hydrogen bond from the Trp312 side chain and other-
wise points away from the protein and into the bulk solvent.
The unexpectedly poor inhibition of AfChiA1 by kinetin can be
explained by the presence of methionine 310 in the AfChiA1 active
site, which replaces an alanine in the corresponding position in
ScCTS1 (Fig. 2A), a substitution found in all A. fumigatus plant-type
chitinases. These residues deﬁne the bottom of the active site
pocket that accepts the furanyl group of kinetin.19 While the pock-
et is still present in AfChiA1, it is shallower due to the larger
Met310 side chain (Fig. 2), rendering it unable to accommodate
bulky ligands like kinetin.
A. fumigatus is predicted to possess ﬁve plant-type GH18 chitin-
ases (AfChiA1–5) thatmay have overlapping, if not interchangeable,
functions. Thus, for an inhibitor to be useful in vivo, it would have to
bind effectively to all ﬁve AfChiA active sites. The AfChiA1 sequence
in Fig. 2A is shaded based on a sequence alignment of AfChiA1–5,
indicating residues identical among all ﬁve proteins in purple, res-
idues conserved among four or fewer proteins in shades of blue and
completely non-conserved residues in white. The same colouring
has also been applied to the AfChiA1 active site surface shown in
Fig. 2C, demonstrating that, with the exception of the non-con-
served but ﬂexible Tyr125,21 the part of the active site cleft interact-
ing with acetazolamide is completely conserved among all ﬁve A.
fumigatus plant-type chitinases. This suggests that acetazolamide
could bind similarly, both in orientation and in afﬁnity, to these ﬁve
enzymes. Fig. 2C also highlights additional conserved active site
areas that could be used for the further elaboration of the ligand.
To investigate in silico the potential for such elaboration, we
used the docking program LIGTOR18 to screen for beneﬁcial substitu-
tions/modiﬁcations of either the acetamido or the sulfonamide
group, while keeping the rest of the molecule constant. Not surpris-
ingly, the scope for modiﬁcation at the acetamido group is limited.Docking runs predict that a slight increase in size of this group, for
example, by substituting a triﬂuoroacetamido moiety, could im-
prove overall binding afﬁnity, and even an additional methyl group,
yielding a propionamido group, may be tolerated with slight
changes to the overall bindingmode, but anything larger (including,
e.g., isobutyramido groups) cannot be accommodated in the active
site pocket and would most likely abolish binding. Modiﬁcations/
substitutions of the sulphonamide group on the other hand face
the opposite problem: as the ligand is essentially pointing away
from the active site, most small modiﬁcations are tolerated but do
not yield additional interactions between ligand and protein. Larger
additions to the existing scaffold may be able to interact with addi-
tional parts of the AfChiA1 active site, but the required ﬂexibility of
such ligands and the corresponding entropy cost associated with
orienting the ﬂexible parts on binding to the protein could negate
any positive effects on the predicted ligand afﬁnity. To test these
computational predictions, a number of acetazolamide derivatives
were either synthesised or obtained from commercial suppliers
and their binding to AfChiA1 was investigated.2.3. Synthesis and screening of acetazolamide derivatives
As acetozolamide provided an attractive small molecule starting
point for a rational focused inhibitor screen, including a structurally
deﬁned binding mode, a number of analogues were screened
against AfChiA1 (Table 3). The acetazolamide analogues were either
synthesised (Scheme 1) or acquired from commercial sources. The
synthesis of compounds carried out to is shown in the scheme.
Compounds were screened against AfChiA1 in duplicate. The as-
say performance statistics generated from screening plates were
well within acceptable screening parameters (Z0 0.72 ± 0.04) and
the replicate potency determinations correlated well, yielding er-
rors below 45% for all bar one compound (Table 3).
The structures of the compounds allowed determination of the
effects of changing the both the sulphonamide (R1 in Table 3) and
acetamide (R2) portions of the molecule. The screen gave a number
of compounds with potencies in the 100–500 lM range, that is,
similar to the parent compound. A few trends in the SAR can be de-
duced. Increasing the size of the acetamide moiety by adding an
extra methyl (2) or a chloro (20 and 21) substituent leads to a
reduction in activity, while substitution with a triﬂuoroacetamide
group (compare 11 and 15) is energetically neutral or slightly
favourable; this is in accordance with the structural and docking
data, as the methyl of the acetamide group essentially ﬁlls the ac-
tive site pocket as described above. At the same time ‘deacetylat-
ing’ R2 to a free amine also abolishes inhibitory activity (cf. 6).
Replacement of the sulphonamide is generally tolerated: –SH, –
Ph, –CF3 and –Br substituents as R1 (9–12) produce compounds
with similar activity to acetazolamide (1). This is perhaps not sur-
prising as the sulphonamide group does not appear to make signif-
icant interactions with the protein. Nonetheless the R1 substituent
does affect afﬁnity as its removal (R1 = –H, 7) or replacement with
a methyl (R1 = –CH3, 8) again abrogate activity.3. Conclusion
A. fumigatus contains ﬁve plant-type GH18 chitinases; based on
the structural information for AfChiA1, it is predicted that the aceta-
zolamide binding sites of AfChiA1–5 are identical, suggesting it may
be possible to develop compounds that inhibit all of these enzymes.
We have previously reported various inhibitors of ScCTS1; these
showed different inhibition proﬁles against AfChiA1; in particular
the binding pocket which accommodated the acetamide group is
much smaller in the case of AfChiA1 compared to ScCTS1. The most
promising inhibitor was acetazolamide. Although acetazolamide
Figure 2. (A) Structure-based sequence alignment of A. fumigatus ChiA1 and S. cerevisiae CTS1. AfChiA1 secondary structure elements are indicated above the sequence and
labelled. Residue numbers are given for AfChiA1. The ScCTS1 sequence is shaded by sequence similarity between the two enzymes shown (black = identical, grey = chemically
similar residues), while AfChiA1 is shaded by sequence conservation among A. fumigatus ChiA enzymes (purple = 100% identity, then a gradient from blue (mode identical) to
white (less identical)). Residues lining the AfChiA1 active site are highlighted by green ﬁlled circles. (B) Acetazolamide (slate) binding to the active site of AfChiA1. The protein
is shown as a grey cartoon with the side chains of active site residues shown as sticks and labelled. Unbiased (i.e., calculated before the addition of the ligand to the model) rA-
weighted Fo  Fc density for acetazolamide contoured at 3.0r is shown in cyan. Possible hydrogen bonds are indicated as black dotted lines, a water participating in indirect
hydrogen bonding between ligand and protein is shown as a red sphere. (C) The active site cavity of AfChiA1 (with bound acetazolamide) coloured by similarity among AfChiA
proteins as described for panel A. Y125, the only non-conserved residue of the acetazolamide-binding site, is labelled.
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have relatively low molecular weights. Ligand efﬁciency is a good
way to characterise how efﬁciently these core scaffolds bind and
the potential for them to be optimised to low nanomolar com-
pounds.24 Some of the compounds (Table 3) have ligand efﬁciencies
of better than 0.3 kcal mol1 atom1. Therefore these possess the
potential to be elaborated to compounds with IC50 of <10 nM and
molecularweightof <500,providedgoodbinding interactionsare re-
tained. Most of the interactions with the protein are focused around
the amide bond and thiadiazole ring. There is not much scope for
further substitution of the acetyl group as the methyl nearly com-
pletely occupies a small pocket. However the sulphonamide does
not appear to make strong interactions and it is possible to replace
this. Therefore optimisation will have to focus on substitution or
replacement of this sulphonamide and enhancement of the interac-
tions of the thiadiazole core with the protein.
4. Experimental
4.1. Expression and puriﬁcation
AfChiA1 Ser29-Leu335 was expressed and puriﬁed as described
previously.21 Brieﬂy, the enzymewas expressed in Pichia pastoris asa secreted protein. The culture supernatant was subjected to dial-
ysis and concentration, then AfChiA1 was puriﬁed using anion ex-
change chromatography followed by gel ﬁltration. The resulting
pure AfChiA1 protein was used for both kinetic analysis and crys-
tallization trials.
4.2. Crystallisation and structure solution
The protein was concentrated to 36 mg mL1 and crystallized by
hanging drop vapour diffusion as described previously.21 Acetazol-
amide was incorporated by adding the solid ligand to a crystal-con-
taining drop and incubating for 30 min at room temperature. After
cryoprotection by short immersion in 2.5 M Li2SO4, data were col-
lected at 100 K on beamline ID14-EH3 at the European Synchrotron
Radiation Facility (ESRF, Grenoble, France).
Data were processed and scaled to 2.0 Å using HKL software26
and the structure was solved by molecular replacement with
AMoRe27 using the AfChiA1 apo-structure21 as a search model.
Reﬁnement of the AfChiA1–acetazolamide complex structure pro-
ceeded through rounds of minimisation with REFMAC528 and mod-
el building with Coot.29 Ligand coordinates and topologies were
generated with PRODRG.30 PyMol31 and ALINE32 were used in the
preparation of Fig. 2.
Table 3
Activity of compounds investigated
Compd
N
S
N
R1 R
2
IC50 (lM) Hill slope L.E. % inhibition at 1 mM
R1 R2
1 –SO2NH2 –NHCOCH3 164 ± 75 1.1 0.40 88
2 –SO2NH2 –NHCOCH2CH3 315 ± 65 0.71 0.34 76
3 –SO2NH2 –NHCO(CH2)2CH3 >1000 33
4 –SO2NH2 –NHCOCH(CH3)2 >1000 N/A N/A
5 –SO2NH2 –NHCOPh 850 ± 74 0.5 0.23 51
6 –SO2NH2 –NH2 >1000 N/A N/A
7 –H –NHCOCH3 >1000 N/A 25
8 –Me –NHCOCH3 >1000 N/A N/A
9 –SH –NHCOCH3 730 ± 120 1.1 0.43 64
10 –Ph –NHCOCH3 479 ± 210 0.5 0.30 60
11 –CF3 –NHCOCH3 141 ± 210 1.1 0.44 91
12 –Br –NHCOCH3 243 ± 98 0.7 0.65 76
13
O
–NHCOCH3 >1000 N/A 22
14 S
OMe
–NHCOCH3 >1000 38
15 –Ph –NHCOCF3 320 ± 60 1.2 0.26 85
16 Morpholino –NHCOCF3 >1000 N/A 22
17
NN
Cl
–NHCOCF3 >1000 N/A 30
18 –Et –NHCOCH2CH3 >1000 N/A 18
19 –Me –NH2 >1000 N/A 21
20 –CH2CH(CH3)2 –NHCOCH2Cl >1000 N/A N/A
21 –CF3 –NHCOCH2Cl >1000 N/A N/A
22 –CF3 –CO(CH2)2CO2H >1000 N/A N/A
Allosamidin 127 0.12
8-Chloro-theophylline 410 0.33
Kinetin >1000
L.E. = ligand efﬁciency in kcal mol1 atom1.24 This was calculated from the equation: DG = RT ln(1/IC50). IC50 standard deviations calculated with 95% conﬁdence limit.
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Scheme 1. Synthesis of acetazolomide analogues.
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AfChiA1 activity was assayed in McIlvain’s buffer (pH 5.5).33 The
ﬁnal reaction mixture consisted of AfChiA1 (10 nM), 0.05 mg/mL
BSA (Thermo) and 4-methylumbelliferyl b-D-N,N0,N00-triacetylchito-
trioside (Sigma) (100 lM). Final assay volume was 42 ll in 384-well black polystyrene plates with a ﬁnal dimethyl sulphoxide
(DMSO) concentration of 1% in all samples, including controls. Test
and standard compound concentrations ranged from 1000 to
0.15 lM and 10,000 to 1.5 lM, respectively.
Test and standard compounds were placed into columns 1 and
13 of a 384-well polypropylene plate and then serially diluted in
A. W. Schüttelkopf et al. / Bioorg. Med. Chem. 18 (2010) 8334–8340 8339100% DMSO through half log increments using a JANUS 8-channel
Varispan automated workstation (PerkinElmer). This produced a
compound source plate containing 30 test and 2 standard com-
pounds curves (100  ﬁnal assay concentration). From this source
plate, 0.42 ll of each compound concentration was then stamped
into replicate black 384-well polystyrene assay plates using a
Hummingbird (Genomic Solutions).
To the assay plates, 20.8 ll AfChiA1 (20 nM) was added to all
wells with the exception the negative controls. The reaction was
initiated by the addition of 20.8 ll of (200 lM) 4-methylumbellife-
ryl b-D-N,N0,N00-triacetylchitotrioside (stock concentration 200 lM),
both previous additions were executed using a FlexDrop reagent
dispenser (PerkinElmer).
Assay plates were then incubated on a microtitre plate shaker
(Heidolph) at room temperature for 70 min. Fluorescence gener-
ated from the release of 4-methylumbelliferone was quantiﬁed
using an Envision 2102 Multilabel Reader (PerkinElmer) equipped
with 340 nm excitation (band width 60 nm) and 460 nm emission
(band width 25 nm) ﬁlters.
ActivtyBase (Abase) version 5.4 from IDBS was used for the data
processing and analysis. All curve ﬁtting was undertaken using a 4
Parameter Logistic dose–response curve using XLFit 4.2 Model 205.
4.4. Compound Synthesis
4.4.1. Synthesis of 5-amino-2-sulfamoyl-1,3,4-thiadiazole
monohydrochloride (6)
Hydrochloric acid (70 mL, 70.00 mmol, 5.2 equiv) was added to
acetazolamide (2.995 g, 13.34 mmol, 1.0 equiv) and the mixture
stirred for 3 h at reﬂux. The crude material was puriﬁed by column
chromatography (CHCl3/MeOH: 100/0 to 70/30) to yield the prod-
uct (2.768 g, 96%); mp 179–180 C; Rf = 0.26 (CHCl3/MeOH: 80/20);
dH (500 MHz, DMSO) 7.91 (2H, br s, NH2-6), 8.09 (3H, s, NH3-7); dC
(125 MHz, DMSO) 157.8 (C-2), 171.6 (C-5); m/z (ES+): 181.1
([M+HCl]+, 100%); HRMS (ES+) 180.9849. ([M+HCl]+ C2H5N4O2S2
requires 180.9848).
4.4.2. Synthesis of 5-propylamido-2-sulfamoyl-1,3,4-thiadiazole
(2)
5-Amino-2-sulfamoyl-1,3,4-thiadiazole monohydrochloride
(218 mg, 1.01 mmol, 1.0 equiv) was dissolved in DCM (6 mL). Tri-
ethylamine (0.30 mL, 2.16 mmol, 2.1 equiv) was added and the
solution stirred for 1.5 h at rt. Then, propionyl chloride (0.20 mL,
2.26 mmol, 2.2 equiv) was slowly added and the mixture left stir-
ring for 1.5 h at rt. Water (1 mL) was added and the precipitate ﬁl-
tered and dried under vacuum. The solid (158 mg) was puriﬁed by
column chromatography (CHCl3/MeOH: 100/0 to 78/22) to yield
the product (32 mg, 13%); mp 253–255 C; Rf = 0.58 (CHCl3/MeOH:
80/20); dH (500 MHz, DMSO) 1.12 (3H, t, H-10, J = 7.5), 2.55 (2H, q,
H-9, J = 7.5), 8.34 (2H, br s, NH2-6), 13.00 (1H, br s, NH-7); dC
(125 MHz, DMSO) 8.8 (C-10), 28.2 (C-9), 161.2 and 164.1 (C-2
and C-5), 173.0 (C-8); m/z (ES+): 237.0 ([M+H]+, 100%), 495.0
([2M+H]+, 71%); HRMS (ES+) 237.0101. ([M+H]+ C5H9N4O3S2 re-
quires 237.0111).
4.4.3. Synthesis of 5-butyramido-2-sulfamoyl-1,3,4-thiadiazole
(3)
5-Amino-2-sulfamoyl-1,3,4-thiadiazole monohydrochloride
(286 mg, 1.32 mmol, 1.0 equiv) was dissolved in DCM (7 mL). Tri-
ethylamine (0.35 mL, 2.51 mmol, 1.9 equiv) was added and the
solution stirred for 1.5 h at rt. Then, butyryl chloride (0.25 mL,
2.36 mmol, 1.8 equiv) was slowly added and the mixture left stir-
ring for 4 h at rt. Water (1 mL) was added and the precipitate ﬁl-
tered and dried under vacuum. The solid (90 mg) was puriﬁed by
column chromatography (CHCl3/MeOH: 100/0 to 78/22) to yield
the product (79 mg, 24%); mp 244–246 C; Rf = 0.54 (CHCl3/MeOH:80/20); dH (500 MHz, DMSO) 0.91 (3H, t, H-11, J = 7.4), 1.65 (2H,
sext, H-10, J = 7.4), 2.52 (2H, m, H-9), 8.33 (2H, br s, NH2-6),
12.99 (1H, br s, NH-7); dC (125 MHz, DMSO) 13.4 (C-11), 17.9 (C-
10), 36.7 (C-9), 161.1 and 164.2 (C-2 and C-5), 172.2 (C-8); m/z
(ES+): 251.0 ([M+H]+, 73%); 523.0 ([2M+H]+, 100%); HRMS (ES+)
251.0257. ([M+H]+ C6H11N4O3S2 requires 251.0267).
4.4.4. Synthesis of 5-(2-methyl-propylamido)-2-sulfamoyl-
1,3,4-thiadiazole (4)
5-Amino-2-sulfamoyl-1,3,4-thiadiazole monohydrochloride
(274 mg, 1.26 mmol, 1.0 equiv) was dissolved in DCM (7 mL). Tri-
ethylamine (0.35 mL, 2.51 mmol, 2.0 equiv) was added and the
solution stirred for 1.5 h at rt. Then, isobutyryl chloride (0.25 mL,
2.34 mmol, 1.9 equiv) was slowly added and the mixture left stir-
ring for 2 h at rt. Water (1 mL) was added and the precipitate ﬁl-
tered and dried under vacuum. The solid was puriﬁed by column
chromatography (CHCl3/MeOH: 100/0 to 80/20) to yield the prod-
uct (90 mg, 26%); mp 254–255 C; Rf = 0.65 (CHCl3/MeOH: 80/20);
dH (500 MHz, DMSO) 1.16 (6H, d, H-10, J = 6.9), 2.82 (1H, Sept, H-9,
J = 6.8), 8.34 (2H, br s, NH2-6), 13.01 (2H, br s, NH-7); dC (125 MHz,
DMSO) 18.9 (C-10), 33.9 (C-9), 161.3 and 164.3 (C-2 and C-5),
176.1 (C-8); m/z (ES+): 523.0 ([2M+Na]+, 100%), 251.0 ([M+H]+,
33%); HRMS (ES+) 251.0272. ([M+H]+ C6H11N4O3S2 requires
251.0267).
4.4.5. Synthesis of 5-benzylamido-2-sulfamoyl-1,3,4-thiadiazole
(5)
5-Amino-2-sulfamoyl-1,3,4-thiadiazole monohydrochloride
(315 mg, 1.45 mmol, 1.0 equiv) was dissolved in DCM (7 mL). Tri-
ethylamine (0.40 mL, 2.87 mmol, 2.0 equiv) was added and the
solution stirred for 1.5 h at rt. Then, benzoyl chloride (0.30 mL,
2.56 mmol, 1.8 equiv) was slowly added and the mixture left stir-
ring for 2.5 h at rt. Water (1 mL) was added and the precipitate ﬁl-
tered and dried under vacuum. The solid (317 mg) was puriﬁed by
column chromatography (CHCl3/MeOH: 100/0 to 78/22) to yield
the product (36 mg, 09%); mp 260–261 C; Rf = 0.66 (CHCl3/MeOH:
80/20); (found: C, 38.3; H, 3.2; N, 17.9; S, 21.2.
C9H8N4O3S20.7MeOH requires C, 38.0; H, 3.5; N, 18.3; S, 20.9);
dH (500 MHz, DMSO) 7.60 (2H, dt, H-11, J = 7.8, 1.8), 7.71 (1H, tt,
H-12, J = 7.4, 1.2), 8.16 (2H, dd, H-10, J = 8.3, 1.1), 8.38 (2H, br s,
NH2-6), 13.55 (1H, br s, NH-7); dC (125 MHz, DMSO) 128.6 and
128 (C-10 and C-11), 130.9 (C-9), 133.4 (C-12), 162.2 and 164.7
(C-2 and C-5), 165.7 (C-8); m/z (ES+): 285.0 ([M+H]+, 100%), 569.0
([2M+H]+, 20%); HRMS (ES+) 285.0102. ([M+H]+ C9H9N4O3S re-
quires 285.0111).
4.4.6. Synthesis of 5-acetamido-1,3,4-thiadiazole (7)
2-Amino-1,3,4-thiadiazole (161 mg, 1.54 mmol, 1.0 equiv) was
dissolved in DCM (2 mL). Acid chloride (0.15 mL, 2.11 mmol,
1.4 equiv) was slowly added (exothermic), and the mixture stirred
for 5 h at rt. The solution was concentrated after addition of H2O
(1 mL). The crude product was puriﬁed by column chromatography
(CHCl3/MeOH: 100/0 to 90/10) to yield the product (38 mg, 17%);
mp 276–277 C; Rf = 0.83 (CHCl3/MeOH: 80/20); (found: C, 33.9;
H, 3.4; N, 27.6; Cl, 21.8. C4H5N3OS0.03HCl0.18MeOH requires C,
33.5; H, 3.8; N, 28.0; S, 21.4); dH (500 MHz, DMSO) 2.20 (3H, s,
H-8), 9.15 (1H, s, H-2), 12.55 (1H, br s, NH-6); dC (125 MHz, DMSO)
22.4 (C-8), 148.5 (C-5), 158.5 (C-2), 168.6 (C-7); m/z (ES+): 144.0
([M+H]+, 60%), 166.0 ([M+Na]+, 100%); HRMS (ES+) 144.0226.
([M+H]+ C4H6N3OS requires 144.0226).
4.4.7. 5-Acetamido-2-thiol-1,3,4-thiadiazole (9)
5-Amino-1,3,4-thiadiazole-2-thiol (554 mg, 4.08 mmol,
1.0 equiv), acetic anhydride (1.8 mL, 19.08 mmol, 4.7 equiv) and
concd sulphuric acid (20 mL, 0.37 mmol, 0.09 equiv) were stirred
for 30 min on a steam bath. After cooling, the mixture was
8340 A. W. Schüttelkopf et al. / Bioorg. Med. Chem. 18 (2010) 8334–8340concentrated under vacuum, and then puriﬁed by column chroma-
tography (CHCl3/MeOH: 100/0 to 70/30) to yield the product
(22 mg, 03%); mp 293–295 C; Rf 0.24 (CHCl3/MeOH: 90/10);
(found: C, 28.1; H, 3.0; N, 22.5; S, 35.1. C4H5N3OS20.3MeOH re-
quires C, 27.9; H, 3.4; N, 22.7; S, 34.7); dY (500 MHz, DMSO) 2.14
(3H, s, H-9), 12.45 (1H, br s, NH-7), 14.06 (1H, br s, SH-6); dC
(125 MHz, DMSO) 22.3 (C-9), 152.2 (C-5), 169;4 (C-8), 183.5 (C-
2); m/z (ES+): 176.0 ([M+H]+, 100%); HRMS 175.9946. ([M+H]+
C4H6N3OS2 requires 175.9947).
4.4.8. 5-Amino-2-methyl-1,3,4-thiadiazole (19)
Acetyl chloride (0.50 mL, 7.04 mmol, 2.2 equiv) was slowly
added to thiosemicarbazide (291 mg, 3.16 mmol, 1.0 equiv) and
the mixture stirred for 4 h at rt. A solution of NaOH 50% was added
till pH 12–14, and the mixture concentrated under vacuum. The
crude material was puriﬁed by column chromatography (CHCl3/
MeOH: 100/0 to 91/09) to yield the product (85 mg, 23%); mp
273–274 C; Rf = 0.79 (CHCl3/MeOH: 80/20); (found: C, 31.9; H,
4.4; N, 35.4; S, 27.4. C3H5N3S0.05AcOH requires C, 31.5; H, 4.4;
N, 35.6; S, 27.1); dY 500 MHz, DMSO 2.17 (3H, s, H-7), 13.15 (2H,
br s, NH2-6); dC (125 MHz, DMSO) 10.8 (C-7), 148.8 (C-5), 165.8
(C-2); m/z (ES+): 115.8 ([M+H]+, 100%); 253.2 ([2M+Na]+, 100%);
HRMS (ES+) 116.0275. ([M+H]+ C3H6N3S requires 116.0277).
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